CBS 2019
CBSMD教育中心
中 文

二尖瓣/三尖瓣瓣膜

Abstract

Recommended Article

Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads: Data From the TriValve Registry Impact of Transcatheter Mitral Valve Repair on Preprocedural and Postprocedural Hospitalization Rates Thirty-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results MITRA-FR vs. COAPT: Lessons from two trials with diametrically opposed results The Art of SAPIEN 3 Transcatheter Mitral Valve Replacement in Valve-in-Ring and Valve-in-Mitral-Annular-Calcification Procedures The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes Current Status and Future Prospects of Transcatheter Mitral Valve Replacement: JACC State-of-the-Art Review

Review ArticleVolume 75, Issue 20, May 2020

JOURNAL:JACC Article Link

Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review

L Cho, M Davis, and for the ACC CVD Womens Committee Members. Keywords: adverse pregnancy outcomes; aspirin; atrial fibrillation; cardiovascular disease; gestational diabetes

ABSTRACT

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for women in the United States and worldwide. There has been no American College of Cardiology (ACC)/American Heart Association guideline update specifically for the prevention of CVD in women since 2011. Since then, the body of sex-specific data has grown, in addition to updated hypertension, cholesterol, diabetes, atrial fibrillation, and primary prevention guidelines. The ACC CVD in Women Committee undertook a review of the recent guidelines and major studies to summarize recommendations pertinent to women. In this update, the authors address special topics, particularly the risk factors and treatments that have led to some controversies and confusion. Specifically, sex-related risk factors, hypertension, diabetes, hyperlipidemia, anticoagulation for atrial fibrillation, use of aspirin, perimenopausal hormone therapy, and psychosocial issues are highlighted.